What is the recommended assessment and step‑by‑step management for an adult patient presenting with epistaxis, including considerations for hypertension, anticoagulant or antiplatelet use, and posterior bleeds?

Epistaxis Management in Adults

Immediate First-Line Treatment

Apply firm, continuous pressure to the soft lower third of the nose for a full 10–15 minutes without checking if bleeding has stopped—premature release is the most common cause of treatment failure. 1

• Position the patient seated upright with the head tilted slightly forward to prevent blood from entering the airway or stomach 1
• Instruct the patient to breathe through the mouth and expectorate blood rather than swallow it 1
• Compression alone resolves the vast majority of anterior epistaxis cases 1

If Bleeding Persists After 15 Minutes

• Clear the nasal cavity of blood clots by suction or gentle nose blowing 1
• Apply topical vasoconstrictor spray (oxymetazoline or phenylephrine, 2 sprays into the bleeding nostril) and resume firm compression for another 5–10 minutes 1
• Vasoconstrictor application stops bleeding in 65–75% of emergency department cases 1
• Obtain baseline blood pressure before using vasoconstrictors, as approximately 33% of epistaxis patients have undiagnosed hypertension and vasoconstrictors carry increased cardiac risk in this population 1

Localization and Definitive Treatment

• Perform anterior rhinoscopy after clot removal to identify the bleeding source 1
• If anterior rhinoscopy fails to identify the source or bleeding is difficult to control, proceed to nasal endoscopy, which localizes the bleeding site in 87–93% of cases 1

When a Bleeding Point is Identified

• Anesthetize the site with topical lidocaine or tetracaine 1
• Cauterize only the active bleeding point—avoid bilateral simultaneous septal cautery because it markedly increases the risk of septal perforation 1
• Electrocautery is more effective than chemical cauterization, with recurrence rates of 14.5% versus 35.1% 1

Indications for Nasal Packing

Proceed to nasal packing when: 1

• Bleeding persists after 15–30 minutes of proper compression combined with vasoconstrictors
• Life-threatening hemorrhage is present
• A posterior bleeding source is suspected

Packing Material Selection

• For patients on anticoagulants or antiplatelet medications, use only resorbable/absorbable materials (Nasopore, Surgicel, Floseal) to avoid trauma during removal 1
• For patients without bleeding risk factors, either resorbable or non-resorbable materials may be used 1
• Apply saline spray frequently to keep packing moist 1

Management of Anticoagulated/Antiplatelet Patients

Non-Life-Threatening Bleeding

Do not discontinue anticoagulant or antiplatelet agents, nor administer reversal agents or blood products, before attempting first-line local measures (compression, vasoconstrictor, cautery, packing)—local hemostasis is preferred because systemic reversal carries significant risks. 1

• Continue aspirin in patients at high cardiovascular risk; the survival benefits outweigh bleeding risks 1
• For NSAIDs, if discontinuation is necessary, withhold for five elimination half-lives 1

Life-Threatening Bleeding (Severe Epistaxis Criteria)

Severe epistaxis is defined by any of the following: 2

• Posterior nosebleed
• Hemodynamic instability due to blood loss
• Hemoglobin decrease ≥2 g/dL or requirement for ≥2 units RBCs

Reversal strategies for life-threatening hemorrhage only: 1

Medication Class	Reversal Agent
Warfarin	4-factor prothrombin complex concentrate (PCC) + vitamin K (faster than FFP with smaller volume) [1]
Unfractionated heparin/LMWH	Protamine sulfate [1]
Dabigatran	Idarucizumab; if unavailable, 4-factor PCC [1]
Apixaban/Rivaroxaban/Edoxaban	Andexanet alfa (400 mg IV bolus over 15 min, then 480 mg infusion over 2 hours for low-dose; 800 mg bolus over 30 min, then 960 mg over 2 hours for high-dose); if unavailable, 2,000 units 4-factor PCC [1]
Antiplatelet agents	Platelet transfusion (effectiveness depends on timing of last dose) [1]

• Consult the primary team managing anticoagulation before fully reversing a patient's anticoagulation 2
• Discuss continuation or discontinuation of anticoagulant/antiplatelet medication at discharge 2

Hypertension Management

Do NOT routinely lower blood pressure acutely during active epistaxis—excessive reduction can cause or worsen renal, cerebral, or coronary ischemia, particularly in elderly patients with chronic hypertension. 1

• Obtain baseline blood pressure measurement 1
• The association between hypertension and epistaxis (OR 1.532) does not establish causation 2
• Monitor blood pressure and base control decisions on bleeding severity, inability to control bleeding, individual comorbidities, and risks of blood pressure reduction 1

Posterior Epistaxis

• Posterior epistaxis accounts for 5–10% of cases, is more common in older patients, more difficult to control, and has higher likelihood of requiring hospitalization 3
• Use posterior nasal packing with Foley catheter and tranexamic acid-soaked gauze for posterior epistaxis unresponsive to compression 1
• Rebleeding occurs in approximately 30% of posterior epistaxis cases, with 44% of episodes occurring within 24 hours of admission 3
• Pack removal within 48 hours after admission increases rebleeding risk (OR 3.07) 3

Advanced Interventions for Refractory Bleeding

When persistent or recurrent bleeding is not controlled by packing or cautery, evaluate candidacy for surgical arterial ligation or endovascular embolization. 1

• Endoscopic sphenopalatine artery ligation has a 97% success rate versus 62% for conventional packing 1
• Endovascular embolization has an 80% success rate with recurrence rates <10% compared to 50% for nasal packing 1
• Consider these interventions earlier rather than later for continued epistaxis despite initial measures 4

Prevention of Recurrence

• Apply petroleum jelly or lubricating agents to the nasal mucosa 2–3 times daily once bleeding stops 1
• Use saline nasal sprays frequently throughout the day to maintain mucosal moisture 1
• Recommend humidifier use in dry environments 1
• Avoid nose picking, vigorous nose blowing, and nasal decongestants for 7–10 days after treatment 1

Screening for Hereditary Hemorrhagic Telangiectasia (HHT)

Assess for nasal and oral mucosal telangiectasias in patients with recurrent bilateral nosebleeds or family history of recurrent nosebleeds. 2

• HHT occurs in 1 in 5,000–18,000 individuals and is often underdiagnosed 2
• Nosebleeds are the main symptom in >90% of HHT patients 2
• Use resorbable packing materials for HHT patients to minimize trauma 2
• Refer HHT patients to an HHT Center of Excellence 1

Documentation Requirements

Document the following risk factors: 1

• Personal or family history of bleeding disorders (von Willebrand disease, hemophilia)
• All anticoagulant and antiplatelet medications
• Intranasal drug use (corticosteroids increase risk 2.7-fold; cocaine/illicit drugs)
• Duration of bleeding episode
• Prior hospitalization for epistaxis
• Chronic kidney or liver disease
• Prior nasal/sinus surgery
• Nasal oxygen or CPAP use

Red-Flag Criteria Requiring Immediate Escalation

Transfer to emergency department or refer to otolaryngology when: 1

• Active bleeding despite correctly placed packing
• Hemodynamic instability (tachycardia, hypotension, orthostatic changes)
• Bleeding duration >30 minutes over a 24-hour period
• Fever >38.3°C (101°F)
• New visual disturbances
• Dizziness or signs of significant blood loss
• Recurrent bleeding despite appropriate treatment
• Unilateral epistaxis with nasal obstruction, facial pain, or visual changes (suggests mass lesion)

Follow-Up

• Arrange follow-up within 30 days for patients treated with packing, cautery, surgical ligation, or embolization 1
• Adequate follow-up allows assessment for underlying conditions when treatments are ineffective or bleeding recurs 1

Common Pitfalls to Avoid

• Premature release of compression is the most common cause of treatment failure 1
• Bilateral simultaneous septal cautery markedly increases septal perforation risk 1
• Aggressive acute blood pressure lowering can cause end-organ ischemia 1
• Overlooking anticoagulation status—check INR if on warfarin 1
• Delaying endoscopic evaluation after multiple packing failures 1
• Using non-resorbable packing in patients on anticoagulants/antiplatelets 1
• Stopping aspirin in high-risk cardiovascular patients without consultation 1